Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Johnson and Johnson
AstraZeneca
Baxter
McKinsey

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Litigation Details for Procter & Gamble Co. v. Teva Pharmaceuticals (D. Del. 2004)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Procter & Gamble Co. v. Teva Pharmaceuticals (D. Del. 2004)

Docket   Start Trial Date Filed 2004-08-13
Court District Court, D. Delaware Date Terminated 2008-05-23
Cause 35:271 Patent Infringement Assigned To Joseph James Farnan Jr.
Jury Demand None Referred To
Parties TEVA PHARMACEUTICALS U.S.A., INC.; THE PROCTER & GAMBLE COMPANY
Patents 3,591,584; 4,072,746; 4,444,779; 4,621,077; 4,687,777; 5,358,941; 5,622,721; 5,681,590; 5,804,570; 5,994,329; 6,015,801; 6,090,410; 6,096,342; 6,165,513; 6,194,004; 6,465,443
Link to Docket External link to docket
Small Molecule Drugs cited in Procter & Gamble Co. v. Teva Pharmaceuticals
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Procter & Gamble Co. v. Teva Pharmaceuticals (D. Del. 2004)

Date Filed Document No. Description Snippet Link To Document
2006-12-20 100 POST Trial Brief ;s:766: External link to document
2007-07-06 107 Exhibit t.|iSt F’atent l\lo" 4,444,779 (the “'779 Patent”)r The ’779 patent is of particular relevance…ciaimed in the patent in suit Takeda owns U.S, Patent 4,687,777 (the "’?'77 patent") entitled… ’779 patent That patent covers a subset of compounds originally included in the '200 patent application… is not patentable fm D. “if the differences between the subject matter sought to be patented and the …court Hrst considered Takeda’s U.S. Patent 4,287,200 (the “'200 patent"), which was issued on Septernber External link to document
2008-02-28 117 Opinion infringed on United States Patent Nos. 5,538,122 (“the ‘122 Patent”) and 6,096,342.l (D.I. l.) On August 25…the ‘406 patent, and in particular, claim 15 of the ‘406 patent. (Teva PFF 15.) The ‘406 Patent issued …between the ‘406 Patent and ‘122 Patent, and whether such differences render the ‘122 patent obvious. The …matter claimed by the ‘122 patent and the ‘406 patent. For example, the ‘122 patent discloses the design and…double patenting. Obviousness-type double patenting, also known as non-statutory double patenting, is a External link to document
2008-05-27 127 Patent/Trademark Report to Commissioner Attached Order of Final Judgment (*Please note Patent No. 6,096,342 was omitted from the Amended Complaint, …5,583,122 12/10/1996 Procter & Gamble Company 2 6,096,342* 8/1/2000 Procter & Gamble Company 3 4 5 ln…Pharmaceuticals PATENT OR DATE OF PATENT TRADEMARK NO' OR TRADEMARK HOLDER OF PATENT OR TRADEMARK l…I Other Pleading PATENT OR DATE OF PATENT TRADEMARK NO_ OR TRADEMARK HOLDER OF PATENT OR TRADEMARK 1 2… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,583,122; (Attachments External link to document
2005-03-08 16 MEMORANDUM in Support Action No. 04-939: U.S. Patents 5,994,329, 6,432,932, and 6,465,443. These patents include claims for once-weekly…the patents listed in the FDA’s “Orange Book” in connection With that drug, or that those patents are …of bone. The patents listed in the Orange Book for Actonel include P&G’s U.S. Patent 5,583,l22, Which…addition to the ’ 122 patent, the Orange Book also lists for Actonel three patents belonging to Merck, …cases the patents claim risedronate or its use. P&G has a legal interest in all the patents in both External link to document
2005-03-08 17 Notice (Other) Prosecution histories for U.S. Patent Nos. 5,583,122, 5,994,329, 6,432,932, and 6,465,443, including lnterference…lnterference 102,399. U.S. Patent Nos. 5,730,715, 5,869,471, 4,761,406, 4,416,877, and 3,400,150. Tang et al… 2004 23 May 2008 1:04-cv-00940-JJF Patent None District Court, D. Delaware External link to document
2005-03-15 18 Exhibit A - E 811986 Blum ctnl. 4- 514¢'107 [51] ADSTRACT 4,621,077 1111935 Rusinietzl!.\ 514{}03 4,637,'167 811987…DOCUNHENTS '$,4?5,339 A '[/1984 Pilnhfnrd 4,621,077 A nam koszni er nl_ 4,761,406 A moss mm er .1!…United States Patent Daifotis et al. Filed 03/15/2005 (10) Patent No.: (45) Date of patent: US 6,465,…-2 United States Patent Filed 03/15/2005 (3.2) (10) Patent No.: US 6,432,932…infringement oi" limited States Patent NO 6,720,488 (" '488 patent"), which is not at issue External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Baxter
McKesson
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.